This initiative will foster collaborative and coordinated efforts to characterize the underlying genetic architecture of diverse neuropsychiatric phenotypes within and across rare genetic disorders and identify the shared genetic risk across rare and idiopathic neuropsychiatric disorders. Projects from multi-disciplinary teams will utilize genome-wide data to comprehensively assess the contribution of genetic variation to the variable expressivity and incomplete penetrance of neuropsychiatric phenotypes across rare genetic disorders. Projects are encouraged to leverage existing resources, cohorts, and collaborative networks with established infrastructure for consistent and high-quality phenotypic data collection and genomic data generation. Projects should seek to enhance the quality of the phenotypic data available for rare genetic disorders by developing or applying phenotyping methodologies that create a pipeline for standardizing assessments and that cut across rare genetic disorders and across developmental time points. Under this initiative, investigators will form a network to facilitate data sharing and harmonization of clinical and genetic data across different studies within the network, as well as accelerate characterization of genotype to phenotype relationships across rare genetic disorders. This network will also generate a resource of bio-samples, as well as phenotypic and genetic data for broader dissemination to the scientific community.
The National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for Clinical Research Center Grants designed to advance the diagnosis, prevention, treatment, and amelioration of human communication Disorders. For this announcement, Clinical Research is defined as research involving individuals with communication Disorders or data/tissues from individuals with a communication disorder. Examples of such research include but are not limited to, studies of the prevention, pathogenesis, pathophysiology, diagnosis, treatment, management or epidemiology of a disease or disorder of hearing, balance, smell, taste, voice, speech, or language. Proposal of clinical trial research is allowed but not required (optional) for this FOA
The Klarman Family Foundation is interested in providing strategic investment in translational research that will accelerate progress in developing effective treatments for anorexia nervosa, bulimia nervosa and binge eating disorder. The Program's short-term goal is to support the most outstanding science and expand the pool of scientists whose research explores the basic biology of feeding, anorexia nervosa, bulimia nervosa, and/or binge eating disorder. The long-term goal is to improve the lives of patients suffering from these conditions.
Examples of funding areas include but are not limited to molecular genetic analysis of relevant neural circuit assembly and function; genetic and epigenetic research; animal models created by genetically altering neural circuits; and testing of new chemical entities that might be used in animal models as exploratory treatments. Please note that imaging studies involving humans are not eligible.
Investigators conducting research in the neuro-circuitry of fear conditioning or reward behavior may also apply but must justify the relevance of their research projects to the basic biology of eating disorders. Clinical psychotherapeutic studies, medication trials and research in the medical complications of these disorders are outside the scope of this Program.
Neuropsychiatric lupus (NPSLE) refers to manifestations of lupus within the central or peripheral nervous system that contribute to increased morbidity and reduced quality of life. Definitions and diagnostic criteria relevant to NPSLE have been utilized heterogeneously. This makes the reproducibility of findings and direct comparisons of studies from different groups difficult.
In 1999, the American College of Rheumatology (ACR) provided revised nomenclature and case definitions for 19 NPSLE syndromes to help facilitate the adoption of standard language and diagnostic criteria in the study of NPSLE. ACR's report indicates that, according to data published by different groups of investigators, the following NPSLE manifestations are most commonly found: cognitive dysfunction, headache, mood and anxiety disorders, cerebrovascular disease, seizure or seizure disorders, and neuropathy.
This RFA seeks applications whose basic, clinical, or translational research outcomes will significantly enhance current understanding of common manifestations of NPSLE in adult and pediatric popluations, including cognitive dysfunction, headache, mood and anxiety disorders, cerebrovascular disease, seizure or seizure disorders, and neuropathy, as defined by the 1999 American College of Rheumatology definitions of NPSLE manifestations. This RFA focuses on investigations of these common NPSLE manifestations and assumes the use of case definitions
provided by ACR.
HIV-associated neurological disorders (HAND) persist in up to 50% of HIV-patients even when HIV replication is suppressed by combination antiretroviral therapy (cART), which transformed HIV/AIDS from a fatal illness into a chronically managed long-term condition. HIV does not infect neurons, but infects microglia and macrophages in the brain, causing HAND associated neuropathology. HAND epitomizes a series of disorders include Asymptomatic Neurocognitive Impairment (ANI), Mild Neurocognitive Disorder (MND), and HIV-Associated Dementia (HAD). These neurocognitive deficits interfere with psychomotor speed and coordination, diminishing memory and executive functions, and reduce quality of life in long-standing aviremic HIV-positive patients. These clinical challenges mandate research for a better understanding of HIV neuropathology; however, currently there are no effective approaches for HIV-infected live human brain studies or realistic HIV-infected animal models for HIV neuropathology.
Proposed projects MUST include the following components. Applications which lack these three components will be considered non-responsive to the FOA and will not be reviewed. The major thrust of the project MUST involve exploitation of induced microglia and cerebral organoids generated from patient derived iPSC lines to better understand the molecular and cellular mechanisms of HIV-Associated Neurocognitive Disorder (HAND). At least one aim or sub-aim MUST also involve either 1. opioid, cannabinoid, methamphetamine, nicotinic, dopaminergic, or other signaling pathways relevant to addictive substance use, or 2. exposure to addictive substances, or 3. analysis of samples from patients that have used addictive substances or have SUDs.
Through this Funding Opportunity Announcement (FOA), the National Institute of Mental Health (NIMH) seeks applications to develop, sustain, enhance, and enrich a centralized national biorepository for genetic studies of psychiatric disorders for facilitation and acceleration of the scientific understanding of the genetic risk architecture underlying mental disorders. This effort is expected to involve a functionally integrated, multi-disciplinary team that will provide for open sharing of biosamples and data resources through a single, centralized, national resource to advance basic and translational research in the genetics of mental disorders.
The goal of this FOA is to transform our understanding of how dynamic interactions among multiple cell types involved in neuroimmune interactions (e.g., neurons, glia cells, neurovascular units, or other neuroimmune components) mediate the transition from normal central nervous system (CNS) function to disorder conditions. Previous findings have markedly advanced our knowledge of neuroimmune interactions during normal brain function, neurodevelopment, and in the context of established diseases. However, there is a lack of understanding of how multiple neuroimmune components mediate transitions from normal brain function to the early stages of CNS disorders, how changes in immune signaling are integrated into neuronal networks, and how disease progression is orchestrated by multiple neuroimmune components. With this FOA, we encourage projects that combine diverse expertise and use innovative approaches to address these questions at the molecular, cellular, and circuitry levels. The outcomes of this research will provide an integrated view of the dynamic changes among multiple neuroimmune components and how they contribute to the onset and progression of CNS disorders.
"This Funding Opportunity Announcement (FOA) encourages research on the biology of high confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular and circuit substrates of neural function. For the purposes of this FOA, the term "complex" can refer to a multifactorial contribution to risk (e.g., polygenic and/or environmental) and/or highly distributed functional features of the brain disorder. Studies may be either hypothesis-generating (unbiased discovery) or hypothesis-testing in design and may utilize in vivo, in situ, or in vitro experimental paradigms, e.g., model organisms or human cell-based assays. While behavioral paradigms and outcome measures can be incorporated into the research design to facilitate the characterization of intracellular, transcellular and circuit mechanisms, these are neither required nor expected. Studies should not attempt to "model" disorders but instead should aim to elucidate the neurobiological impact of individual or combined risk factor(s), such as the affected molecular and cellular components and their relationships within defined biological process(es). This can include the fundamental biology of these factors, components and processes. The resulting paradigms, component pathways and biological processes should be disseminated with sufficient detail to enrich common and/or federated data resources (e.g., those contributing to the Gene Ontology, Synaptic Gene Ontology, FAIR Data Informatics) in order to bridge the gap between disease risk factors, biological mechanism and therapeutic target identification. The present announcement (R21 activity code) can be used for applications to develop early stage, high-risk, exploratory approaches or establish proof-of-concept where there is little or no preliminary data."
The NARSAD Young Investigator Grant provides support for the most promising young scientists conducting neurobiological research. Two year awards up to $60,000, or $30,000 per year are provided to enable promising investigators to either extend research fellowship training or begin careers as independent research faculty. Basic and/or clinical investigators are supported, but research must be relevant to serious brain and behavior disorders such as schizophrenia, mood disorders, anxiety disorders, or child and adolescent mental illnesses.
A few NARSAD Young Investigators are selected each year to present at the foundation's annual Scientific Symposium in New York City. NARSAD Young Investigators are also eligible to be selected for the Foundation's Freedman Prize for Outstanding Basic Research and Klerman Prize for Outstanding Clinical Research. Selection is based upon outstanding research as outlined in the final progress report of the NARSAD Grant project.
Long-term misuse and chronic exposure to abused substances can produce widespread changes in brain structure and function. Although much progress has been made, additional research is still needed to identify the neurobiological changes that result from substance use, and how these changes contribute to substance use disorders. The overarching goals of the research areas described in this FOA are to understand the neurobiological mechanisms underlying substance use disorders, with special emphasis on identifying changes and neuroadaptations that occur during dependence, withdrawal, and relapse to chronic substance use. An understanding of the basic mechanisms underlying substance use disorders can help to identify targets for prevention and treatment interventions. Research utilizing basic, translational, or clinical approaches is appropriate.
Founded in 1972, the Tourette Association of America has emerged as the premier national nonprofit organization working to make life better for all people affected by Tourette and tic disorders. The association advances its work by raising public awareness and fostering social acceptance; working to advance scientific understanding, treatment options, and care; educating professionals to better serve the needs of children, adults, and families challenged by Tourette and tic disorders; advocating for public policies and services that promote positive school, work, and social environments; providing help, hope, and a supportive community across the nation; and empowering its community to deal with the complexities of this spectrum of disorders.
To that end, grants of up to $150,000 over two years will be awarded for basic and clinical studies related to any aspect of Tourette syndrome.
To be eligible, investigators are required to have an advanced degree such as a PhD, MD, or equivalent or be an allied professional with an advanced degree in a related field. Investigators from nonprofit and for-profit organizations are eligible to apply.
Pre-proposals must be received no later than November 1, 2017. Upon review, selected applicants will be invited to submit a full application by February 15, 2018.
Long-term misuse and chronic exposure to abused substances can produce widespread changes in brain structure and function. Although much progress has been made, additional research is still needed to identify the neurobiological changes that result from substance use, and how these changes contribute to substance use disorders. The overarching goals of the research areas described in this FOA are to understand the neurobiological mechanisms underlying substance use disorders, with special emphasis on identifying changes and neuroadaptations that occur during dependence, withdrawal, and relapse to chronic substance use. An understanding of the basic mechanisms underlying substance use disorders can help to identify targets for prevention and treatment interventions. Research utilizing basic, translational, or clinical approaches is appropriate.
Founded in 1972, the Tourette Association of America (formerly known as the Tourette Syndrome Association) has emerged as the premier national nonprofit organization working to make life better for all people affected by Tourette and tic disorders. The association advances its work by raising public awareness and fostering social acceptance; working to advance scientific understanding, treatment options, and care; educating professionals to better serve the needs of children, adults, and families challenged by Tourette and tic disorders; advocating for public policies and services that promote positive school, work, and social environments; providing help, hope, and a supportive community across the nation; and empowering its community to deal with the complexities of this spectrum of disorders.
To that end, grants of up to $150,000 over two years will be awarded for basic and clinical studies on all aspects of Tourette syndrome.
To be eligible, investigators are required to have an advanced degree such as a Ph.D., M.D. or equivalent or be allied professionals with advanced degrees such as R.N.s, Drs. of O.T., social workers, and related fields. Investigators from nonprofit and for-profit organizations can apply.
This Funding Opportunity Announcement (FOA) encourages Exploratory/Developmental Research Project Grant (R21) applications from institutions/organizations that propose to study the neuroimmune mechanisms of alcohol related disorders. Studies using animal models and post-mortem human alcoholic brains suggest that alcohol exposure alters the neuroimmune system in the brain. However, it remains unclear how the altered neuroimmune signaling contributes to brain functional and behavioral changes associated with alcohol dependence. Recent studies reveal that neuroimmune molecules are expressed in neurons and glia, and play an important role in modulating synaptic function, neurodevelopment, and neuroendocrine function. These neuromodulatory properties, together with their essential roles in neuroinflammation, provide a new frame work to understand the role of neuroimmune factors in mediating neuroadaptation and behavioral phenotypes associated with alcohol use disorders. Studies supported by this FOA will provide fundamental insights of neuroimmune mechanisms underlying brain functional and behavioral changes induced by alcohol.
This Funding Opportunity Announcement (FOA) encourages Exploratory/Developmental Research Project Grant (R21) applications from institutions/organizations that propose to study the neuroimmune mechanisms of alcohol related disorders. Studies using animal models and post-mortem human alcoholic brains suggest that alcohol exposure alters the neuroimmune system in the brain. However, it remains unclear how the altered neuroimmune signaling contributes to brain functional and behavioral changes associated with alcohol dependence. Recent studies reveal that neuroimmune molecules are expressed in neurons and glia, and play an important role in modulating synaptic function, neurodevelopment, and neuroendocrine function. These neuromodulatory properties, together with their essential roles in neuroinflammation, provide a new frame work to understand the role of neuroimmune factors in mediating neuroadaptation and behavioral phenotypes associated with alcohol use disorders. Studies supported by this FOA will provide fundamental insights of neuroimmune mechanisms underlying brain functional and behavioral changes induced by alcohol.
This Funding Opportunity Announcement (FOA) encourages Exploratory/Developmental Research Project Grant (R21) applications from institutions/organizations that propose to study the neuroimmune mechanisms of alcohol related disorders. Studies using animal models and post-mortem human alcoholic brains suggest that alcohol exposure alters the neuroimmune system in the brain. However, it remains unclear how the altered neuroimmune signaling contributes to brain functional and behavioral changes associated with alcohol dependence. Recent studies reveal that neuroimmune molecules are expressed in neurons and glia, and play an important role in modulating synaptic function, neurodevelopment, and neuroendocrine function. These neuromodulatory properties, together with their essential roles in neuroinflammation, provide a new frame work to understand the role of neuroimmune factors in mediating neuroadaptation and behavioral phenotypes associated with alcohol use disorders. Studies supported by this FOA will provide fundamental insights of neuroimmune mechanisms underlying brain functional and behavioral changes induced by alcohol.
This FOA encourages Research Project Grant (R01) applications from institutions/organizations that propose to study the neuroimmune mechanisms of alcohol-related disorders. Studies using animal models and post-mortem human alcoholic brains suggest that alcohol exposure alters the neuroimmune system in the brain. However, it remains unclear how the altered neuroimmune signaling contributes to brain functional and behavioral changes associated with alcohol dependence. Recent studies reveal that neuroimmune molecules are expressed in neurons and glia, and play an important role in modulating synaptic function, neurodevelopment, and neuroendocrine function. These neuromodulatory properties, together with their essential roles in neuroinflammation, provide a new frame work to understand the role of neuroimmune factors in mediating neuroadaptation and behavioral phenotypes associated with alcohol use disorders. Studies supported by this FOA will provide fundamental insights of neuroimmune mechanisms underlying brain functional and behavioral changes induced by alcohol.
This Funding Opportunity Announcement (FOA) encourages exploratory/developmental research grant applications, proposing the development of innovative, collaborative research projects on brain and other nervous system function and disorders throughout life, relevant to low- and middle-income countries (LMICs). Research on neurological, mental, behavioral, alcohol and substance use disorders may span the full range of science from basic to implementation research. Scientists in the United States (U.S.) or upper-middle income countries (UMICs) are eligible to partner with scientists in LMIC institutions. Scientists in upper middle-income LMICs (UMICs) are also eligible to partner directly with scientists at other LMIC institutions with or without out a US partner. Income categories used are as defined by the World Bank at http://data.worldbank.org/about/country-classifications/country-and-lending-groups.
This Funding Opportunity Announcement (FOA) encourages exploratory/developmental research grant applications, proposing the development of innovative, collaborative research projects on brain and other nervous system function and disorders throughout life, relevant to low- and middle-income countries (LMICs). Research on neurological, mental, behavioral, alcohol and substance use disorders may span the full range of science from basic to implementation research. Scientists in the United States (U.S.) or upper-middle income countries (UMICs) are eligible to partner with scientists in LMIC institutions. Scientists in upper middle-income LMICs (UMICs) are also eligible to partner directly with scientists at other LMIC institutions with or without out a US partner. Income categories used are as defined by the World Bank at http://data.worldbank.org/about/country-classifications/country-and-lending-groups. These grants are expected to foster the development of more comprehensive research programs that contribute to the long-term goals of building sustainable research capacity in LMICs to address nervous system development, function and impairment throughout life and to lead to diagnostics, prevention, treatment and implementation strategies. The proposed work may also contribute to developing a base for research networking and evidence-based policy beyond the specific research project.
This Funding Opportunity Announcement (FOA) encourages exploratory/developmental research grant applications, proposing the development of innovative, collaborative research projects on brain and other nervous system function and disorders throughout life, relevant to low- and middle-income countries (LMICs). Research on neurological, mental, behavioral, alcohol and substance use disorders may span the full range of science from basic to implementation research. Scientists in the United States (U.S.) or upper-middle income countries (UMICs) are eligible to partner with scientists in LMIC institutions. Scientists in upper middle-income LMICs (UMICs) are also eligible to partner directly with scientists at other LMIC institutions with or without out a US partner. Income categories used are as defined by the World Bank at http://data.worldbank.org/about/country-classifications/country-and-lending-groups.